Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
NCT03941236Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- May 2019
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of dasiglucagon in congenital hyperinsulinism (HI), sponsored by Zealand Pharma. Primary endpoint: Adverse Events up to 3 years. Started May 2019; status: completed.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT03941236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941236.